Orum Therapeutics closed a financing of roughly 146 billion Korean won (about $100 million) to advance a pipeline that merges antibody targeting with protein‑degrader payloads. The company plans to accelerate ORM‑1153, a CD123‑targeting degrader‑antibody conjugate aimed at acute myeloid leukemia (AML), toward clinical testing by late 2026. Orum’s CEO, Sung Joo Lee, told reporters the company shelved an earlier HER2 program after liver‑toxicity signals but emphasized the platform remained intact. Orum has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals that span early‑stage assets and potential licensing. Investors backed the play that degraders as payloads could bypass resistance mechanisms seen with conventional ADC cytotoxins. The raise will fund toxicology, CMC and IND‑enabling work while the company tightens focus on hematology indications where CD123 is overexpressed.